CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price
Jan 10
Have your own idea? Try our Stock Screener
Australian (ASX) Biotech Industry Analysis
UpdatedJan 24, 2025
DataAggregated Company Financials
Companies32
- 7D-1.5%
- 3M-5.0%
- 1Y-2.0%
- YTD-3.4%
Over the last 7 days, the Biotech industry has dropped 1.5%, driven by a pullback from CSL of 1.1%. In contrast, Mesoblast has gained 6.7%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 15% annually.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 24 Jan 2025 | AU$146.8b | AU$24.5b | AU$3.7b | 23.8x | 40x | 6x |
| Sun, 22 Dec 2024 | AU$148.5b | AU$24.6b | AU$3.7b | 24.1x | 40.4x | 6x |
| Tue, 19 Nov 2024 | AU$145.0b | AU$23.8b | AU$3.5b | 25.6x | 40.9x | 6.1x |
| Thu, 17 Oct 2024 | AU$157.6b | AU$23.1b | AU$3.4b | 28.2x | 46.1x | 6.8x |
| Sat, 14 Sep 2024 | AU$156.6b | AU$23.0b | AU$3.4b | 29.4x | 46x | 6.8x |
| Mon, 12 Aug 2024 | AU$159.6b | AU$22.4b | AU$3.3b | 31.5x | 48.5x | 7.1x |
| Wed, 10 Jul 2024 | AU$153.8b | AU$21.9b | AU$3.2b | 31.8x | 48x | 7x |
| Fri, 07 Jun 2024 | AU$150.9b | AU$22.2b | AU$3.3b | 31.2x | 46.4x | 6.8x |
| Sun, 05 May 2024 | AU$143.1b | AU$22.2b | AU$3.3b | 30.2x | 44x | 6.4x |
| Tue, 02 Apr 2024 | AU$147.5b | AU$22.5b | AU$3.3b | 30.3x | 44.7x | 6.5x |
| Thu, 29 Feb 2024 | AU$145.6b | AU$22.6b | AU$3.4b | 29.9x | 43.4x | 6.5x |
| Sat, 27 Jan 2024 | AU$149.0b | AU$20.8b | AU$2.8b | 34.1x | 53.9x | 7.1x |
| Mon, 25 Dec 2023 | AU$143.3b | AU$20.2b | AU$2.7b | 34.3x | 53.8x | 7.1x |
| Wed, 22 Nov 2023 | AU$130.7b | AU$20.9b | AU$2.8b | 32x | 47x | 6.3x |
| Fri, 20 Oct 2023 | AU$120.1b | AU$21.7b | AU$2.9b | 29.3x | 41.3x | 5.5x |
| Sun, 17 Sep 2023 | AU$137.1b | AU$21.4b | AU$2.8b | 32.1x | 49x | 6.4x |
| Tue, 15 Aug 2023 | AU$134.8b | AU$18.5b | AU$2.4b | 37.7x | 56.2x | 7.3x |
| Thu, 13 Jul 2023 | AU$135.8b | AU$18.0b | AU$2.3b | 36.5x | 58.5x | 7.6x |
| Sat, 10 Jun 2023 | AU$155.9b | AU$17.9b | AU$2.3b | 40.9x | 67.4x | 8.7x |
| Mon, 08 May 2023 | AU$154.3b | AU$17.8b | AU$2.3b | 41.4x | 67.3x | 8.7x |
| Wed, 05 Apr 2023 | AU$148.5b | AU$17.8b | AU$2.3b | 40.2x | 64.9x | 8.3x |
| Fri, 03 Mar 2023 | AU$148.9b | AU$17.8b | AU$2.3b | 41.1x | 64.9x | 8.4x |
| Sun, 29 Jan 2023 | AU$150.7b | AU$15.2b | AU$2.4b | 55.5x | 63.1x | 9.9x |
| Tue, 27 Dec 2022 | AU$147.5b | AU$16.0b | AU$2.6b | 46.2x | 57.8x | 9.2x |
| Thu, 24 Nov 2022 | AU$152.2b | AU$16.2b | AU$2.6b | 43x | 58.8x | 9.4x |
| Sat, 22 Oct 2022 | AU$137.0b | AU$17.0b | AU$2.7b | 39.3x | 50.2x | 8.1x |
| Mon, 19 Sep 2022 | AU$145.8b | AU$16.0b | AU$2.6b | 45.8x | 56.9x | 9.1x |
| Wed, 17 Aug 2022 | AU$151.2b | AU$15.3b | AU$2.8b | 42.1x | 54.9x | 9.9x |
| Fri, 15 Jul 2022 | AU$149.9b | AU$15.9b | AU$2.9b | 38.4x | 52.2x | 9.4x |
| Sun, 12 Jun 2022 | AU$136.7b | AU$15.3b | AU$2.8b | 34.4x | 49.5x | 8.9x |
| Tue, 10 May 2022 | AU$136.4b | AU$15.1b | AU$2.8b | 35.4x | 49.4x | 9x |
| Thu, 07 Apr 2022 | AU$136.3b | AU$14.1b | AU$2.6b | 39.8x | 53.4x | 9.6x |
| Sat, 05 Mar 2022 | AU$132.0b | AU$14.7b | AU$2.7b | 40.1x | 49.5x | 9x |
| Mon, 31 Jan 2022 | AU$133.0b | AU$15.0b | AU$2.9b | 36.3x | 46.5x | 8.9x |
Price to Earnings Ratio
46.5x
Current Industry PE
- Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 40.0x which is lower than its 3-year average PE of 51.8x.
- The 3-year average PS ratio of 7.8x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have grown 8.7% per year over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.65% | |
| Healthcare | 0.09% | |
| Biotech | -1.53% | |
| Biotech | -1.53% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MSB Mesoblast | AU$2.87 | 6.7% +AU$490.2m | 983.0% | PS386.2x | |
| TLX Telix Pharmaceuticals | AU$27.53 | 3.5% +AU$314.6m | 143.6% | PE187.4x | |
| OPT Opthea | AU$0.97 | 18.9% +AU$190.8m | 99.0% | PS2881.5x | |
| OCC Orthocell | AU$1.59 | 16.1% +AU$52.6m | 292.6% | PS71.6x | |
| ARX Aroa Biosurgery | AU$0.78 | 6.1% +AU$15.5m | 6.8% | PS3.9x |